Initial Experience with Fractionation Mapping in the Identification of Vagal Ganglionated Plexus During Cardioneuroablation

This is a series case report of five symptomatic patients presented with diagnosis of sinus bradycardia, first and second degrees atrioventricular (AV) blocks, that were referred to pacemaker implantation. During the screening, a functional cause for the bradycardia and AV blocks were documented by treadmill stress test, 24-hour Holter monitoring and atropine test. After the confirmation of the diagnosis, patients were submitted to cardioneuroablation on an anatomical basis supported by a tridimensional electroanatomical fractionation mapping software. The technique and the acute and short-term results of the cardioneuroablation are described

Initial Experience with Fractionation Mapping in the Identification of Vagal Ganglionated Plexus During Cardioneuroablation

This is a series case report of five symptomatic patients presented with diagnosis of sinus bradycardia, first and second degrees atrioventricular (AV) blocks, that were referred to pacemaker implantation. During the screening, a functional cause for the bradycardia and AV blocks were documented by treadmill stress test, 24-hour Holter monitoring and atropine test. After the confirmation of the diagnosis, patients were submitted to cardioneuroablation on an anatomical basis supported by a tridimensional electroanatomical fractionation mapping software. The technique and the acute and short-term results of the cardioneuroablation are described

Functional Activation Mapping of Scar-Related Ventricular Tachycardia Substrate

The optimal method to identify the arrhythmogenic substrate of scar-related ventricular tachycardia (VT) is unknown. Sites of activation slowing during sinus rhythm (SR) often co-localize with the VT circuit. This is a report of two scar related VT substrate mapping using a strategy of voltage-independent approach.

Functional Activation Mapping of Scar-Related Ventricular Tachycardia Substrate

The optimal method to identify the arrhythmogenic substrate of scar-related ventricular tachycardia (VT) is unknown. Sites of activation slowing during sinus rhythm (SR) often co-localize with the VT circuit. This is a report of two scar related VT substrate mapping using a strategy of voltage-independent approach.

Initial Experience and Results of Combined Treatment for Atrial Fibrillation: Catheter Ablation with High-Power Short Duration Ablation and Left Atrial Appendage Closure

Introduction: Long-term freedom from atrial fibrillation (AF) after catheter ablation and, consequently, the potential for stroke reduction remain unpredictable. Recently, left atrial appendage closure (LAAC) became an effective mechanical alternative to oral anticoagulation (OAC) for stroke prevention in AF patients. Objective: This study aims to evaluate the feasibility and safety of combined treatment for AF with catheter ablation (CA) with the high-power short duration technique associated with LAAC in one single procedure. Methods: Patients with non-valvular AF who underwent combined CA and LAAC procedure were included in the retrospective observational study. Between April 2018 and October 2020, 13 patients with AF were included, eight (61,54%) males, eight (61.54%) with persistent AF (PersAF), mean age 68.54 (65–84) years old, mean time from AF diagnosis to treatment 13.08 (3–33) months, mean CHA2VASC2 5.08 (3–7), all patients with coronary or vascular disease, 12 (92.31%) with hypertension, five (38.46%) with left ventricular dysfunction, four (30.77%) prior strokes using OAC and four (30.77%) patients with diabetes. Indications for LAAC included history of contraindication to OAC because of severe bleeding in eight (61.54%), previous stroke in four (30.77%) and two (13.08%) patients with LAA thrombus, despite the use of two different OAC (one associated with bleeding). One patient had a pseudoaneurysm in femoral artery, and two patients died of non-procedure complications after 30 days. At six months, angiotomography showed successful complete sealing of the LAA in seven (77.72%) of nine patients evaluated, and the two patients without it had a leak of less than 2 mm. After mean follow-up of 14 months (five to 33), 10 (90.91%) of the 11 patients were in sinus rhythm. Three (27.27%) patients, one in blanking period, recovered sinus rhythm after amiodarone. No cardioembolic or bleeding events occurred. Conclusion: In this small observational study, we showed the feasibility and safety of the combined therapy with AF catheter ablation with LAAC with a high rate of sinus rhythm and no cardioembolic event

Initial Experience and Results of Combined Treatment for Atrial Fibrillation: Catheter Ablation with High-Power Short Duration Ablation and Left Atrial Appendage Closure

Introduction: Long-term freedom from atrial fibrillation (AF) after catheter ablation and, consequently, the potential for stroke reduction remain unpredictable. Recently, left atrial appendage closure (LAAC) became an effective mechanical alternative to oral anticoagulation (OAC) for stroke prevention in AF patients. Objective: This study aims to evaluate the feasibility and safety of combined treatment for AF with catheter ablation (CA) with the high-power short duration technique associated with LAAC in one single procedure. Methods: Patients with non-valvular AF who underwent combined CA and LAAC procedure were included in the retrospective observational study. Between April 2018 and October 2020, 13 patients with AF were included, eight (61,54%) males, eight (61.54%) with persistent AF (PersAF), mean age 68.54 (65–84) years old, mean time from AF diagnosis to treatment 13.08 (3–33) months, mean CHA2VASC2 5.08 (3–7), all patients with coronary or vascular disease, 12 (92.31%) with hypertension, five (38.46%) with left ventricular dysfunction, four (30.77%) prior strokes using OAC and four (30.77%) patients with diabetes. Indications for LAAC included history of contraindication to OAC because of severe bleeding in eight (61.54%), previous stroke in four (30.77%) and two (13.08%) patients with LAA thrombus, despite the use of two different OAC (one associated with bleeding). One patient had a pseudoaneurysm in femoral artery, and two patients died of non-procedure complications after 30 days. At six months, angiotomography showed successful complete sealing of the LAA in seven (77.72%) of nine patients evaluated, and the two patients without it had a leak of less than 2 mm. After mean follow-up of 14 months (five to 33), 10 (90.91%) of the 11 patients were in sinus rhythm. Three (27.27%) patients, one in blanking period, recovered sinus rhythm after amiodarone. No cardioembolic or bleeding events occurred. Conclusion: In this small observational study, we showed the feasibility and safety of the combined therapy with AF catheter ablation with LAAC with a high rate of sinus rhythm and no cardioembolic event

Detecçao de Taquiarritmias Atriais em Portadores de Marcapassos Bicamerais

Introduçao: O estudo comparou o diagnóstico de taquiarritmias atriais (TA) em portadores de marcapassos bicamerais detectadas por eletrocardiogramas de 12 derivaçoes (ECG) realizados durantes consultas clínicas e avaliaçoes de marcapasso, com detecçoes de TA dos dispositivos implantados. Casuística e método: em uma amostra de 65 pacientes, foram implantados e avaliados marcapassos bicamerais (DDDR) capazes de detectar e gravar eletrogramas atriais (EGM). As principais indicaçoes para o implante foram a doença do nó sinusal (DNS) e o bloqueio atrioventricular total (BAVT). O seguimento foi realizado por meio de ECG seriados e avaliaçoes de marcapasso realizadas uma semana, um, três, seis, nove e 12 meses após o implante. Resultados: TA foram detectadas por ECG em seis pacientes e pelos EGM em 49. Nove apresentaram sintomas; dois, alteraçoes eletrocardiográficas significativas e cinco, gravaçoes relevantes nos geradores. Os sintomas foram mais presentes em pacientes com TA diagnosticadas pelos EGM e naqueles com história prévia de TA. Discussao: Em portadores de marcapassos bicamerais, as TA geralmente sao diagnosticadas por meio de ECG, Holter ou de manifestaçoes clínicas, porém os dispositivos implantados têm revelado validade, qualidade e confiabilidade para realizar esse diagnóstico. Conclusao: As TA foram mais frequentes em análises dos EGM e pacientes com diagnóstico prévio de arritmias. Nao houve diferença na incidência de TA nas indicaçoes do marcapasso (DNS vs. BAVT). O uso dos eletrogramas dos dispositivos permitiu realizar maior número de diagnósticos, indicando que podem ser úteis no acompanhamento dos pacientes que recebem terapêutica medicamentosa para tais arritmias

Detecçao de Taquiarritmias Atriais em Portadores de Marcapassos Bicamerais

Introduçao: O estudo comparou o diagnóstico de taquiarritmias atriais (TA) em portadores de marcapassos bicamerais detectadas por eletrocardiogramas de 12 derivaçoes (ECG) realizados durantes consultas clínicas e avaliaçoes de marcapasso, com detecçoes de TA dos dispositivos implantados. Casuística e método: em uma amostra de 65 pacientes, foram implantados e avaliados marcapassos bicamerais (DDDR) capazes de detectar e gravar eletrogramas atriais (EGM). As principais indicaçoes para o implante foram a doença do nó sinusal (DNS) e o bloqueio atrioventricular total (BAVT). O seguimento foi realizado por meio de ECG seriados e avaliaçoes de marcapasso realizadas uma semana, um, três, seis, nove e 12 meses após o implante. Resultados: TA foram detectadas por ECG em seis pacientes e pelos EGM em 49. Nove apresentaram sintomas; dois, alteraçoes eletrocardiográficas significativas e cinco, gravaçoes relevantes nos geradores. Os sintomas foram mais presentes em pacientes com TA diagnosticadas pelos EGM e naqueles com história prévia de TA. Discussao: Em portadores de marcapassos bicamerais, as TA geralmente sao diagnosticadas por meio de ECG, Holter ou de manifestaçoes clínicas, porém os dispositivos implantados têm revelado validade, qualidade e confiabilidade para realizar esse diagnóstico. Conclusao: As TA foram mais frequentes em análises dos EGM e pacientes com diagnóstico prévio de arritmias. Nao houve diferença na incidência de TA nas indicaçoes do marcapasso (DNS vs. BAVT). O uso dos eletrogramas dos dispositivos permitiu realizar maior número de diagnósticos, indicando que podem ser úteis no acompanhamento dos pacientes que recebem terapêutica medicamentosa para tais arritmias

The First-Pass Isolation Effect in High-Power Short-Duration Compared to Low-Power Long-Duration Atrial Fibrillation Ablation: a Predictor of Success

Introduction: Different results are described after atrial fibrillation ablation and multiples predictors of recurrence are well established. Objective: Evaluate and analyze if first-pass isolation effect (FPI) during first atrial fibrillation (AF) ablation with high-power short-duration (HPSD) comparing to low-power long-duration (LPLD) can impact on late outcome. Methods: Observational, retrospective study, 144 patients submitted to HPSD and LPLD ablation. HPSD: 71 patients, 50 (70.42%) males, mean age 59.73 years, 52 (73.24%) hypertension, 44 (61.97%) obstructive apnea, 23 (32.39%) arterial disease, 20 (28.17%) diabetes, and 10(14.08%) stroke. CHADS2VASC2 2.57. CT: 73 patients, 50 (68.49%) males, mean age 60.7 years, 53 (72.60%) hypertension, 41 (56.16%) obstructive apnea, 28 (38.36%) arterial disease, 14 (19.17%) diabetes and 8 (10.96%) stroke. CHAD2SVASC2 2.22. Results: Recurrence occurred in 33 patients (22.92%) at 12 months follow-up, HPSD with 9 patients and LPLD with 24 patients. Higher rate of bilateral FPI were observed in HPSD patients with 62 of 71 patients comparing to 17 of 73 patients in LPLD (P < 0.00001). At the end of study 62 (87.32%) of 71 HPSD patients were in sinus rhythm comparing to 49 (67.12%) of 73 patients in LPLD (P 0.0039). Conclusion: HPSD ablation produced higher rates of FPI comparing to LPLD. HPSD compared to LPLD showed a superiority in maintaining sinus rhythm at 12 months. At patients submitted to HPSD protocol ablation, FPI could predict higher rate of sinus rhythm at 12 months follow-up.

The First-Pass Isolation Effect in High-Power Short-Duration Compared to Low-Power Long-Duration Atrial Fibrillation Ablation: a Predictor of Success

Introduction: Different results are described after atrial fibrillation ablation and multiples predictors of recurrence are well established. Objective: Evaluate and analyze if first-pass isolation effect (FPI) during first atrial fibrillation (AF) ablation with high-power short-duration (HPSD) comparing to low-power long-duration (LPLD) can impact on late outcome. Methods: Observational, retrospective study, 144 patients submitted to HPSD and LPLD ablation. HPSD: 71 patients, 50 (70.42%) males, mean age 59.73 years, 52 (73.24%) hypertension, 44 (61.97%) obstructive apnea, 23 (32.39%) arterial disease, 20 (28.17%) diabetes, and 10(14.08%) stroke. CHADS2VASC2 2.57. CT: 73 patients, 50 (68.49%) males, mean age 60.7 years, 53 (72.60%) hypertension, 41 (56.16%) obstructive apnea, 28 (38.36%) arterial disease, 14 (19.17%) diabetes and 8 (10.96%) stroke. CHAD2SVASC2 2.22. Results: Recurrence occurred in 33 patients (22.92%) at 12 months follow-up, HPSD with 9 patients and LPLD with 24 patients. Higher rate of bilateral FPI were observed in HPSD patients with 62 of 71 patients comparing to 17 of 73 patients in LPLD (P < 0.00001). At the end of study 62 (87.32%) of 71 HPSD patients were in sinus rhythm comparing to 49 (67.12%) of 73 patients in LPLD (P 0.0039). Conclusion: HPSD ablation produced higher rates of FPI comparing to LPLD. HPSD compared to LPLD showed a superiority in maintaining sinus rhythm at 12 months. At patients submitted to HPSD protocol ablation, FPI could predict higher rate of sinus rhythm at 12 months follow-up.